The model was trained with patients from the Spanish National Cancer Registry for GEP-NENs, R-GETNE (data cut-off date for analyses: December 2018), a hospital registry managed by the GETNE group (Grupo Español de Tumores Neuroendocrinos for its Spanish acronym), in which 60 centres representing all regions of the country are currently participating, and data from 3971 patients have been reported.

For this analysis, patients with initially non-curable metastatic disease were selected. However, as time goes by, it is possible that some patients have received locoregional therapies, which may have modified PFS. In addition, patients may have unusual risk factors not adequately captured by the model. For this reason, predictions should be considered as orientative, and interpreted with caution.

The nomogram was built with a lognormal accelerated failure time model. Non-linear and dynamic effects of the variables were taken into account. Predictors were selected according to criteria of frequency, prior theoretical knowledge, and accessibility in clinical practice. Finally, the model was validated by a series of 97 patients from Christie Hospital (Manchester, UK).


Carmona-Bayonas A, Jiménez-Fonseca P, et al. (2019). Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study. Journal of Clinical Oncology, 2019. DOI: 10.1200/JCO.19.00980